Showing 1461-1470 of 3020 results for "".
- Bonti's Novel Gateway Neuromodulator Performs Well in Phase 2A Studyhttps://practicaldermatology.com/news/bontis-novel-serotype-e-botulinum-toxin-performs-well-in-phase-2a-study/2458094/Bonti’s lead product candidate, EB- 001, passed muster in a Phase 2A study for the treatment of glabellar lines. EB-001 is a novel serotype E botulinum neurotoxin with a unique efficacy profile, characterized by fast onset of action (about 24 hours
- Environmental Groups Sue FDA to Take Formaldehyde Out of Salonshttps://practicaldermatology.com/news/environmental-groups-sue-fda-to-take-formaldehyde-out-of-salons/2458096/The Environmental Working Group (EWG) and Women’s Voices for the Earth (WVE) are suing the Food and Drug Administration (FDA) because of the group’s failure to act on dangerous hair straighteners that contain unsafe levels of formaldehyde and pose a significant health hazard to consum
- Dr. Larry Brilliant to Give Keynote at ASDS 2017 Meetinghttps://practicaldermatology.com/news/dr-larry-briiliant-to-give-keynote-at-asds-2017-meeting/2458097/Larry Brilliant, MD, MPH, Chair of the Skoll Global Threats Fund in San Francisco and former Vice President and Executive Director of Google, is slated to give the opening keynote address at The
- Glenmark Pharmaceuticals Reports Positive Phase 2a Data for GBR 830 for Atopic Dermatitishttps://practicaldermatology.com/news/glenmark-pharmaceuticals-reports-positive-phase-2a-data-for-gbr-830-for-atopic-dermatitis/2458102/Glenmark Pharmaceuticals shared positive data from a Phase 2a study of GBR 830, an investigational, anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis (AD). The study evaluated the safety, biological and clinical activity, and pharmacokinetics of GBR 830, relative to placebo, i
- Innovation in Action: Meet the DNA Sunscreen that Gets Better the Longer You Wear Ithttps://practicaldermatology.com/news/innovation-in-action-meet-a-dna-sunscreen-that-gets-better-the-longer-you-wear-it/2458109/Researchers at Binghamton University, State University of New York have developed a coating made out of DNA that gets better at protecting skin from Ultraviolet light the more you expose it to the sun, and it also keeps your skin hydrated. “Ultraviolet (UV) light can actually damage
- Histogen's Growth Factor Technology Now Part of Allergan's Skin Care Linehttps://practicaldermatology.com/news/histogens-growth-factor-technology-now-part-of-allergan-skin-care-line/2458111/Histogen’s growth factor technology will be marketed as part of Allergan's skin care line within its recently acquired Regenica® Advanced Rejuvenation System. The Regenica line is based on multipotent CCM Complex (Cell Conditioned Media) which comprises active growth factors
- Patent Challenge Filed for Generic Version Of Soolantra Creamhttps://practicaldermatology.com/news/patent-challenge-filed-for-generic-version-of-soolantra-cream/2458120/Perrigo Company plc's subsidiary has filed a Paragraph IV Abbreviated New Drug Application with the FDA for a generic version of Soolantra® (ivermectin) cream, 1%. Following notification from Perrigo, Galderma Laboratories, L.P., Galderma S.A., and Nestle Skin Health S.A., filed a
- Galderma CareConnect Patient Savings Card Program Passes Milestonehttps://practicaldermatology.com/news/galderma-careconnect-patient-savings-card-program-passes-milestone/2458119/The Galderma CareConnect patient savings program has surpassed the mark of 1,000,000 prescriptions filled through its patient access program. Committed to keeping accessibility remarkably simple and saving patients’ money, the company says the program is structured to work at any accredited
- Congrats! ASDSA SUNucate Initiative Named Power of A Gold Award Winnerhttps://practicaldermatology.com/news/congrats-asdsa-sunucate-initiative-named-power-of-a-gold-award-winner/2458134/The American Society for Dermatologic Surgery Association (ASDSA) received a Power of A Gold Award from the American Society of Association Executives (ASAE) for its SUNu
- EMA Grants Orphan Status to Tarix's EB Candidiatehttps://practicaldermatology.com/news/ema-grants-orphan-status-to-tarixs-eb-candidiate/2458160/The European Medicines Agency (EMA) granted Orphan Drug status to Tarix Orphan LLC’s lead compound, TXA127, for the treatment of epidermolysis bullosa (EB). TXA127 is a pharmaceutical grade formulation of the naturally occurring peptide